Insights of Acute Lymphoblastic Leukemia with Development of Genomic Investigation

Abstract

Treatment outcomes for acute lymphoblastic leukemia (ALL), especially pediatric ALL, have greatly improved due to the risk-adapted therapy. Combination of drug development, clinical practice, as well as basic genetic researches has brought the survival rate of ALL from less than 10% to more than 90% today, not only increasing the treatment efficacy but also limiting adverse drug reactions (ADRs). In this review, we summarized the landscape identification of ALL genetic alterations, which provided the opportunity to increase the survival rate and especially minimize the relapse risk of ALL, and highlighted the importance of the development of new technologies of genomic investigation for translational medicine.

Keywords: Acute lymphoblastic leukemia; Adverse drug reactions; Big data; Bioinformatics; Drug efficacy; Genomic landscape; Microarray; Mutation; Next-generation sequencing; Single nucleotide polymorphism; Translational medicine.